Bavarian Nordic
198.4
DKK
+3.09 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
51 following
+3.09%
-11.23%
-27.14%
+11.37%
+11.81%
+32.53%
-35.14%
+54.53%
+39.1%
www.bavarian-nordic.com/investor.aspx
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
10.33
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
192.45 / 199
DKK
Market cap
15.64B DKK
Turnover
76.47M DKK
Volume
388K
Latest videos
Financial calendar
Annual report
2025-03-05
General meeting
2025-04-09
Interim report
2025-05-09
Interim report
2025-08-22
Interim report
2025-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
ShowingAll content types
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine
Bavarian Nordic Upgrades its Financial Guidance for 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools